Related Experiment Video
Updated: Aug 9, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Small Cell Lung Cancer in Light/Never Smokers - A Role for Molecular Testing?
Gordon Taylor Moffat1, Tao Wang2, Andrew G Robinson1
1Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.
Abstract:
This report describes the management of small cell lung cancer (SCLC) transformation in a patient with untreated ALK-mutated advanced disease and a minimal smoking history, and a separate case of a de novo SCLC in a lifelong nonsmoker found to have a potentially targetable ERBB2 alteration. In the first case, chemotherapy followed by a targeted inhibitor was chosen due to the presence of the ALK rearrangement, as well as a somewhat discordant response to induction chemotherapy, suggesting possible progression of the ALK inhibitor-sensitive component. Molecular testing for the identification of driver mutations should be considered in patients with SCLC who have light/never smoking histories in order to help understand the incidence and ultimate optimal management strategies.
Insights
Small cell lung cancer (SCLC) transformation and de novo SCLC cases highlight the importance of molecular testing. Identifying driver mutations like ALK and ERBB2 in light/never smokers can guide targeted therapy and improve SCLC management strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Small cell lung cancer (SCLC) is typically associated with heavy smoking.
- Driver mutations are increasingly identified in various cancer types, guiding treatment.
- Understanding SCLC heterogeneity and rare genetic alterations is crucial for effective management.
Purpose of the Study:
- To describe the management of SCLC transformation in an ALK-mutated patient.
- To report a de novo SCLC case with an ERBB2 alteration in a nonsmoker.
- To emphasize the role of molecular testing in specific SCLC patient populations.
Main Methods:
- Case report analysis of two distinct SCLC scenarios.
- Review of treatment strategies including chemotherapy and targeted inhibitors.
- Molecular testing for driver mutations (ALK, ERBB2) in SCLC patients.
Main Results:
- One patient with SCLC transformation and ALK mutation received chemotherapy followed by a targeted inhibitor.
- A separate de novo SCLC case in a nonsmoker revealed a potentially targetable ERBB2 alteration.
- Discordant response to chemotherapy suggested progression of the ALK inhibitor-sensitive component.
Conclusions:
- Molecular testing for driver mutations is recommended for SCLC patients with light or never smoking histories.
- Identifying targetable alterations like ALK and ERBB2 can inform optimal management strategies for SCLC.
- Further research is needed to understand the incidence and impact of driver mutations in specific SCLC subtypes.
